TrialBlood2014

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.

Timothy P Hughes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.